---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-016314"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2023-04-04T23:59:59+00:00"
generated_at: "2026-06-17T06:20:56.923516+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharmaceuticals appoints Mark White as CMO; Schwartz shifts to Chief Gene Therapy Officer

## Summary
- Mark White appointed Chief Medical Officer effective April 4, 2023; previously Global Franchise Head for Fasenra at AstraZeneca.
- Jonathan Schwartz transitions to newly created Chief Gene Therapy Officer, focusing on gene therapy strategy and external opportunities.
- White receives $450k base salary, 45% target bonus, and ~$2M equity grant (1/3 options, 2/3 RSUs) with standard vesting.

## SEC filing metadata
- accession: 0001140361-23-016314
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2023-04-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036123016314/0001140361-23-016314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036123016314/brhc10051024_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-016314
- JSON: https://secwatch.observer/filing/0001140361-23-016314.json
- Plain text: https://secwatch.observer/filing/0001140361-23-016314.txt

## Key facts
- Executive change
  Jonathan Schwartz changed role as Chief Gene Therapy Officer at ROCKET PHARMACEUTICALS, INC..
  - Action: transitioned
  - Role: Chief Gene Therapy Officer
  source text: On April 4, 2023, Jonathan Schwartz transitioned from Chief Medical Officer of Rocket Pharmaceuticals, Inc. (the “ Company ”) to Chief Gene Therapy Officer,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036123016314/0001140361-23-016314-index.htm
- Executive change
  Mark White was appointed as Chief Medical Officer at ROCKET PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: Additionally, on April 4, 2023, Mark White joined the Company as its new Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036123016314/0001140361-23-016314-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.